The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer()

During exclusive curative radiotherapy for head and neck tumors, the patient’s organs at risk (OAR) and target volumes frequently change size and shape, leading to a risk of higher toxicity and lower control than expected on planned dosimetry. Adaptive radiotherapy is often necessary but 1) tools ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Esteyrie, Vincent, Gleyzolle, Baptiste, Lusque, Amélie, Graff, Pierre, Modesto, Anouchka, Rives, Michel, Lapeyre, Michel, Desrousseaux, Jacques, Graulières, Eliane, Hangard, Gregory, Arnaud, François-Xavier, Ferrand, Regis, Delord, Jean-Pierre, Poublanc, Muriel, Mounier, Muriel, Filleron, Thomas, Laprie, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429538/
https://www.ncbi.nlm.nih.gov/pubmed/30949592
http://dx.doi.org/10.1016/j.ctro.2019.02.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429538/
https://www.ncbi.nlm.nih.gov/pubmed/30949592
http://dx.doi.org/10.1016/j.ctro.2019.02.006

Ejemplares similares